Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Health insurer Cigna hints at easing COVID-19 pain, backs profit goal

Published 11/04/2021, 06:08 AM
Updated 11/04/2021, 11:15 AM
© Reuters. FILE PHOTO: A screen displays the logo for Cigna Corp. on the floor at the New York Stock Exchange (NYSE) in New York, U.S., July 16, 2019. REUTERS/Brendan McDermid

By Manojna Maddipatla and Amruta Khandekar

(Reuters) -Cigna Corp on Thursday joined rival U.S. health insurers in signaling a lower hit from costs related to COVID-19 next year and maintained its target of at least 10% earnings growth over a newly raised 2021 adjusted profit estimate.

Shares were up about 2% in early trade.

Larger rivals UnitedHealth Group (NYSE:UNH) and Anthem also raised their 2021 adjusted profit view and forecast smaller pandemic impact next year as infections decline and more people get inoculated.

Cigna (NYSE:CI) moderately raised its outlook for 2021 adjusted profit from operations by 15 cents to at least $20.35 per share, including a negative impact from COVID-19. The company, however, did not specify how much the impact would be per share.

"As time progresses, COVID-related impacts and the ongoing performance of the business are becoming more intertwined. Therefore, we no longer believe it's instructive to continue to quantify the impact of COVID-19," Cigna's Chief Financial Officer Brian Evanko said.

Cigna had forecast a hit of about $2.50 per share to its 2021 adjusted earnings in August.

The company's decision to not quantify the impact indicates "it was a material headwind in 2021 that should subside in 2022," Cowen analyst Gary Taylor said.

Cigna reported better-than-expected third-quarter profit on the back of a near 13% jump in revenue from its health services unit that includes the pharmacy benefits management business.

However, its medical care ratio (MCR), the amount spent on medical claims versus income from premiums, worsened to 84.4% in the third quarter from 82.6% a year earlier, compared with an estimate of 83.93%, according to four analysts polled by Refinitiv.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

The company now expects 2021 MCR to be between 84.0% and 84.5%, up from its prior forecast of 83.0% to 84.0%.

Excluding special items, Cigna's income from operations was $5.73 per share, above analysts' estimate of $5.23 per share, according to Refinitiv IBES data.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.